-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.INR↓
Bajaj HealthCare Limited outperformed den DAX um +373 % vom 10.05.2016 bis 01.10.2021
Dir gefallen die Informationen zu Bajaj HealthCare Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Bajaj HealthCare Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Bajaj HealthCare Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Bajaj HealthCare Limited?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
16 News & Informationen zur Bajaj HealthCare Limited Aktie
Sensex, Nifty Hit Lifetime Highs; Nifty Nears 16k
Big results are lined up for today for the April-June quarter of FY22. Companies including Bharti Airtel, Adani Enterprises, Adani Ports and Special Economic Zone, Bajaj Healthcare, Bank of India, Barbeque-Nation Hospitality, and Dabur India will release their results later in the day, , sensex, stockmarket
Bajaj Healthcare stock hits all-time high on DRDO's nod to Covid-19 drug
Share of Bajaj Healthcare rose 10.83% to all-time high of Rs 1,009.8 against previous close of Rs 911.10 on BSE
Mankind Pharma gets approval to manufacture, market Covid drug 2-DG
Our objective behind this agreement is to ensure maximum reach of this medication to the deserving Indian patients suffering from the deadly pandemic, the company said.It will manufacture the product at its facilities in Visakhapatnam and Himachal Pradesh
Bajaj Healthcare shares hit new 52-week high after receiving DRDO nod to manufacture, sell its COVID-19 drug
Bajaj Healthcare said in a regulatory filing that it has received a licence from Defence Research and Development Organisation (DRDO) to Manufacture and Market of ‘2-Deoxy-D-Glucose’ as approved medication for the treatment of COVID-19 patients.
Bajaj Healthcare soars 11% on receiving DRDO licence to manufacture and market oral Covid drug
Shares of Bajaj Healthcare surged 11 per cent in early trade on Thursday after the company received license from Defence Research and Development Organisation (DRDO) to manufacture and market '2-Deoxy-D-Glucose' (2-DG). This drug is used in control and treatment of Covid-19, which is given as an oral intake to the patients suffering from the virus.
Bajaj Healthcare surges 11% on receiving DRDO nod to manufacture 2-DG
Read more about Bajaj Healthcare surges 11% on receiving DRDO nod to manufacture 2-DG on Business Standard. The company has received a licence from DRDO to manufacture and market “2-Deoxy-D-Glucose” (2-DG) as approved medication for the treatment of COVID-19 patients
All eyes on TCS results
Market expected to open in a narrow range
Info Edge, TCS, HDFC, Shyam Metalics, Bajaj Healthcare, RailTel Corporation stocks in focus
Nifty futures were trading 63 points or 0.40 per cent down at 15,825.50 on Singaporean Exchange, suggesting a negative start for BSE Sensex and Nifty 50 on weekly F&O expiry day
Trade setup for Thursday: Top 15 things to know before Opening Bell
Any sustainable move above 15,900 levels may cause momentum towards 16,000-16,050 levels, says Rajesh Palviya of Axis Securities.
Covid-19: Bajaj Health gets DRDO license to make 2-DG drug
The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy' Laboratories.The Centre has recently launched 2-DG as an anti -Covid-19 therapeutic application of the drug 2-Deoxy-D-glucose
Bajaj Healthcare to list on NSE
The board of Bajaj Healthcare on Monday approved the listing on the National Stock Exchange of India. The company has about 1.38 crore outstanding shares of ₹10 each. While promoters hold 67.26 per ce
Market Wrap Podcast, June 29: Here's all that happened in the markets today
Read more about Market Wrap Podcast, June 29: Here's all that happened in the markets today on Business Standard. BSE Sensex ended the day at 52,549 levels, down 186 points or 0.35 per cent while the broader 50-share Nifty closed at 15,748 levels, down 66 points
Sensex Drops 186 Points; Nifty Ends Below 15,750
(RTTNews) – Indian shares ended lower for a second straight session on Tuesday, with banks, metals and automakers pacing the decliners amid concer…
Bajaj Healthcare zooms 20% as Co seeks compulsory licence for Baricitinib
Read more about Bajaj Healthcare zooms 20% as Co seeks compulsory licence for Baricitinib on Business Standard. The company has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug “Baricitinib” (API and formulation)
Bajaj Healthcare requests Indian patent office to grant compulsory licence for COVID-19 drug
The firm approached the Indian Patent Office after Eli Lilly & Company on two occasions declined to sign the voluntary licence for manufacturing and supply of COVID-19 drug Baricitinib
Active Pharmaceutical Ingredient Market Revenue To Reach ~$300 Billion by 2030: P&S Intelligence
/PRNewswire/ — The global active pharmaceutical ingredient (API) market is set for rapid expansion in the coming years, primarily because of the increasing…